Adenocarcinoma of the prostate is the most prevalent neoplastic disease in
men and continues to be a major cause of morbidity and mortality. Death fro
m prostate cancer is associated with objective and biochemical progression
following hormonal manipulations often described as hormone refractory pros
tate cancer (HRPCA). Therapy for HRPCA is primarily palliative and therapeu
tic efficacy has to be balanced against potential treatment-related side ef
fects. Therapeutic efficacy may be assessed by evaluating the percentage of
patients obtaining a PSA decline of >50%, evaluating the response of bidim
ensionally measurable disease or by improvements in quality of life assessm
ents. The most effective cytotoxic therapies at the present time seem to be
combinations of estramustine phosphate with taxanes and etoposide. Regimes
employing ketoconazole with estramustine, vinblastine or bisphosphonates s
eem to be worthy of further evaluation. Mitoxantrone has an impressive pall
iative effect in patients, particularly when combined with hydrocortisone.
Oral chemotherapeutic regimens with a combination of estramustine phosphate
, cyclophosphamide and prednisone appear to offer a less toxic alternative.
For the future we need prospective randomized clinical phase-III studies,
prognosticators identifying patients as being at high or low risk who might
benefit from different therapeutic approaches and generally binding eligib
ility and response guidelines in order to be able to compare trials of diff
erent therapeutic approaches. Copyright (C) 2001 S. Karger AG, Basel.